Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07214571 · ClinicalTrials.gov registry record · Phase 2
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
A Phase 2 study of Respiratory Syncytial Virus Infections, sponsored by Shionogi.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 192
- Enrollment target
- 20
- Study locations
NCT07214571 is a Phase 2 study of Respiratory Syncytial Virus Infections that is actively recruiting participants, run by Shionogi. The registered enrollment target is 192 participants, below the 1,082-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT07214571, a Phase 2 study of Respiratory Syncytial Virus Infections, is actively recruiting participants, sponsored by Shionogi.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 192 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk factors for progression to severe RSV infection starting intervention within 72 hours of RSV symptom onset.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG S-337395
Study Locations (20)
Florida
- Hope Clinical Trials - 3970 W Flagler St. - Coral Gables
- Beautiful Minds Clinical Research Center - Cutler Bay
- Doral Medical Research - Hialeah
- Southern Clinical Research - Miami
- LCC Medical Research - Miami - BTC - PPDS - Miami
- Nuren Medical and Research Center - Miami
- Continental Clinical Research, LLC - Miami
- Dynamic Medical Research, LLC - Miami - Miami
- Miami Clinical Research, LLP. - Miami
- Reed Medical Research - Miami
- Palm Springs Community Health Center - Miami Lakes
- Oceanic Research Group, LLC - North Miami Beach
- CDC Research Institute, LLC - Port Saint Lucie
- Cordova Research Insittute - Sweetwater
- Better Life Clinical Research LLC - Tampa
- Research Bay,Inc. - Tampa
- Santos Research Center - 5927 Webb Rd - Tampa
California
- LA Universal Research Center, Inc. - Los Angeles
- Med Partnes, Inc - Elligo- PPDS - Toluca Lake
Georgia
- Covenant Pulmonary Criticial Care and Research Ins - East Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2025-12-11 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07214571
The ClinicalTrials.gov registry entry for NCT07214571 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,082-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (82% lower). The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07214571 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT07214571 about?
NCT07214571 is a clinical study titled "A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease". The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk factors for progression to severe RSV infection starting intervention within 72 hours of RSV symptom onset.
What is the current status of trial NCT07214571?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 192 participants. The study started on 2025-12-11. Estimated completion is 2026-12-30.
What conditions does trial NCT07214571 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections.
What interventions are being tested in trial NCT07214571?
The interventions under investigation include: Placebo (DRUG), S-337395 (DRUG).
Who is sponsoring clinical trial NCT07214571?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07214571 being conducted?
This trial has 20 study locations across California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
RECRUITING · Phase 2
-
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
COMPLETED · Phase 2
-
A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above
COMPLETED · Phase 2
-
A Study of BLB-201 RSV Vaccine in Infants and Children
RECRUITING · Phase 1
-
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
RECRUITING · Phase 3
-
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.